Trastuzumab/Hyaluronidase

曲妥珠单抗/透明质酸酶

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab/Hyaluronidase
Drug Alias NameHyaluronidase-oysk/TrastuzumabTrastuzumab/Hyaluronidase-oyskHerceptin Hylecta
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsHyaluronic acid modulators
TargetsHyaluronic acidReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/02/28
Country/TerritoryUnited States
CombinationsYes Hyaluronidase recombinant humanTrastuzumab
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksN/A